Top Income Companies To Buy For 2015

During the second quarter David Einhorn of Greenlight Capital bought seven new stocks. The guru�� portfolio now carries 30 stocks and is valued at $5.33 billion.

David Einhorn�� Top Five Holdings:

Apple (AAPL)

Einhorn�� largest holding is in Apple. The guru currently holds 2,397,706 shares, representing 0.26% of the company�� shares outstanding and a massive 17.8% of his total portfolio.

The guru did not make any changes to his holdings in Apple over the second quarter.

Einhorn�� holding history of Apple as of the second quarter:

[ Enlarge Image ]

The company designs, manufactures, and markets personal computers, mobile communication devices, and portable digital music and video players and sell a variety of related software, services, peripherals and networking solutions.

Apple�� historical revenue and net income:

[ Enlarge Image ]

Best Paper Stocks To Watch For 2016: Costco Wholesale Corporation(COST)

Costco Wholesale Corporation operates membership warehouses that offer a selection of branded and private label products in a range of merchandise categories in no-frills, self-service warehouse facilities. The company's product categories include candy, snack foods, tobacco, alcoholic and non-alcoholic beverages, and cleaning and institutional supplies; appliances, electronics, health and beauty aids, hardware, office supplies, garden and patio, sporting goods, toys, seasonal items, and automotive supplies; dry and institutionally packaged foods; apparel, domestics, jewelry, house wares, media, home furnishings, cameras, and small appliances; meat, bakery, deli, and produce; and gas stations, pharmacy, food court, optical, one-hour photo, hearing aid, and travel. It also provides business and gold star (individual) membership services. As of April 26, 2011, the company operated 581 warehouses, including 425 in the United States and Puerto Rico, 80 in Canada, 22 in the Uni ted Kingdom, 7 in Korea, 6 in Taiwan, 8 in Japan, 1 in Australia, and 32 in Mexico. It also has Costco Online, an electronic commerce Web site, at costco.com in the United States and at costco.ca in Canada. The company was formerly known as Costco Companies, Inc. and changed its name to Costco Wholesale Corporation in August 1999. Costco Wholesale Corporation was founded in 1976 and is based in Issaquah, Washington.

Advisors' Opinion:

• [By Amanda Alix]

  Why now?
  Reuters notes�that, while Walmart's retirement plan has high turnover and relatively small account balances, which might dull interest in taking over the plan, its sheer size is unusual, and may be why Wells Fargo (NYSE: WFC  ) has entered into talks concerning taking over administrative duties from BAML. Bank of America is involved in these talks, too, which may turn into a bidding war. According to benefits company Brightscope, other large retailers such as Costco (NASDAQ: COST  ) and Target (NYSE: TGT  ) each have plans with assets in the $5 billion range.

• [By David Hanson]

  If done correctly, establishing or increasing a fee can avoid public outrage and be a great thing for shareholders. In late 2011, the beloved retailer Costco (NASDAQ: COST  ) clearly communicated to its member its intention to increase its annual membership fee by 10%, and in 2012, the company saw its highest annual membership renewal rate -- nearly 90% in the United States.

• [By Geoff Gannon] f 26 and then setting off to prove that Wal-Mart�� prospects are every bit as good as Costco�� is a terrible idea. If you want to buy Wal-Mart stock you need only prove that Wal-Mart is selling for less than the business is worth. You don�� need to know why Wal-Mart sells for less than Costco or Dollar General (DG). In fact, you don�� even need to know how high or low Wal-Mart�� P/E is compared to those businesses. You only need to know one price and understand the value of one business.

  And yet, many of the value investing blogs and articles I read start their discussion of why some stock is such a great investment by explaining what the market�� consensus view is and why that conventional wisdom is wrong.

  This is a terrible idea because:

  1. Market prices are complex. Buy and sell decisions are complex. Comparing your view of the future with the market�� view of the future assumes we can offer a distinct reason for why people buy and sell stocks. Can we really be more specific than people sell stocks because they don�� want to hold them and they buy stocks because they do want to hold them?

  I�� skeptical about the idea of understanding the reasons for people�� buy and sell decisions. People are attracted to certain stocks and repulsed by others. These feelings aren�� totally unexplainable. I�� sure we can partially explain why certain celebrities are found especially attractive or repulsive by the general public. We could probably do the same for why certain stocks are found especially attractive or repulsive by the investing public. Beyond laying down some general principles of what investors do and don�� find attractive in a stock ��I think we�� mostly just be entertaining ourselves making up stories about stocks instead of just valuing stocks.

  2. We intend to take advantage of the market price. If we let the market price influence our opinion of the company we are taking an input and letting it pass t

Top Income Companies To Buy For 2015: Westfield Group (WEFIF)

Westfield Group is engaged in ownership, development, design, construction, funds/asset management, leasing and marketing activities undertaken with respect to its global portfolio of retail properties. Property investments segment includes net property income from existing shopping centers and completed developments, revaluation of existing centers and other operational expenses. Property and project management segment includes income from third parties, property management and development fees, and associated business expenses. The development segment includes revaluation of redevelopments and development projects. The corporate business unit includes unallocated corporate entity expenses. In November 2013, Starwood Capital Group LLC acquired a majority interest in seven regional malls in the United States from the Westfield Group. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australian stocks fell early Wednesday, tracking a weak lead from the U.S. but with a few blue-chip miners higher after gains for some commodities overnight. The S&P/ASX 200 (AU:XJO) retreated 0.4% to 5,237.80 after similar losses for the main Wall Street indexes, with the Australian benchmark trading around its lowest level since October. Among the major decliners, Qantas Airways Ltd. (AU:QAN) (QUBSF) lost 2.5%, Harvey Norman Holdings Ltd. (AU:HVN) (HNORY) gave up 1.3%, and Incitec Pivot Ltd. (AU:IPL) (ICPVY) fell 1.8%. Santos Ltd. (AU:STO) (STOSF) fell 2.6% on indication it will miss its lowered production guidance for 2013, according to the Australian Financial Review. On the upside, top miners BHP Billiton Ltd. (AU:BHP) (BHP) and Rio Tinto Ltd. (AU:RIO) (RIO) rose 0.3% and 0.7%, respectively, while Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) traded 1% higher. Shares of global shopping-mall developer Westfield Group Australia (AU:WDC) (WEFIF) were on halt

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australia stocks tilted lower early Monday as the Sydney markets reacted to last week's disappointing jobs numbers out of the U.S., with the S&P/ASX 200 (AU:XJO) down 0.2% at 5,304.40. Data out Friday showed the U.S. added a net 74,000 jobs, trailing a forecast for 193,000 positions, and while Wall Street ended mixed following the numbers, Australian stocks will global exposure moved lower. Financial major Macquarie Group Ltd. (AU:MQG) (MCQEF) fell 1.8%, mall developer Westfield Group Australia (AU:WDC) (WEFIF) retreated 0.6%, and media firm News Corp. (AU:NWS) (NWS) -- the parent of MarketWatch, publisher of this report -- gave up 1.3%. But the jobs report also depressed the U.S. dollar, which helped boost prices for dollar-denominated commodities, and this in turn supported Australian resource shares. BHP Billiton Ltd. (AU:BHP) (BHP) gained 0.6%, Rio Tinto Ltd. (AU:RIO) (RIO) added 0.9%, Alumina Ltd. (AU:AWC) (AWCMF) rallied 4.5%, and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) improved by 1.2%. A strong showing for Comex gold on Friday also sent Newcrest Mining Ltd.

Top Income Companies To Buy For 2015: Wolseley PLC (WOS)

Wolseley plc is a specialist trade distributor of plumbing and heating products to professional contractors and a supplier of building materials in North America, the United Kingdom and Continental Europe. The Company operates in seven segments: USA, UK, Canada, Nordic, France, Central and Eastern Europe, and Group. On September 1 2009, the Company acquired Decorative Product Source, Inc, a company engaged in the distribution and supply of construction materials and services. On January 8, 2010, the Company disposed of 100% of Wolseley Ireland Holdings Limited, which comprised all the Company's businesses in the Republic of Ireland and the Brooks business in Northern Ireland. In November 2011, the Company announced that it had completed the sale of its remaining interest in Stock Building Supply to The Gores Group. In April 2012, the Company sold its Brossette, the French Plumbing and Heating business to Saint Gobain. In October 2012, the Company acquired Davis & Warshow, Inc. Advisors' Opinion:

• [By Inyoung Hwang]

  Wolseley Plc (WOS) added 3.1 percent to 3,296 pence, its largest gain in more than five weeks. The world�� biggest distributor of plumbing and heating products said so-called trading profit in the 12 months through July climbed to 725 million pounds ($1.2 billion) from 665 million pounds a year earlier. Analysts had predicted earnings of 704 million pounds, according to the average of 20 estimates compiled by the company. Wolseley proposed a special dividend payout of 300 million pounds.

Top Income Companies To Buy For 2015: Shire PLC (SHPG)

Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.

VANSE/ VENVANSE

VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.

ADDERALL XR

ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.

INTUNIV

INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.

EQUASYM

Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.

LIALDA/MEZAVANT

LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.

PENTASA

PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.

RESOLOR

RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.

XAGRID

XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.

REPLAGAL

REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.

ELAPRASE

ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.

VPRIV

VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.

FIRAZYR

FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.

DERMAGRAFT

DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.

The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.

Advisors' Opinion:

• [By Jesse Solomon]

  A flurry of acquisitions has already occurred in the past few years. Most recently, the Irish pharmaceutical conglomerate Shire (SHPG) bought Pennsylvania-based ViroPharma for $4.2 billion late last year. The deal gave Shire access to Cinryze, medicine for a rare blood disorder.

• [By Ben Levisohn]

  AbbVie (ABBV) has dipped 2.1% to $56.21 after upping its bid for Shire (SHPG) to more than $51 billion. Shire has risen 0.9% to $239.65.

  Delta Air Lines (DAL) has fallen 1.7% to $36.26 after it said it would cut some 85% of its flights to Venezuela to reduce its exposure to the bolivar.

• [By George Budwell]

  Shire plc (NASDAQ: SHPG  ) is in the process of buying orphan drug-specialist ViroPharma (NASDAQ: VPHM  ) for $4.2 billion, strengthening Shire's already robust commercial drug portfolio for rare diseases. The deal is expected to be finalized no later than Jan. 9, after Shire extended its tender offer to acquire all outstanding ViroPharma shares last week.

• [By Alexander Maxwell]

  The market for the treatment of chronic diabetic foot ulcers has been growing and larger companies have been taking notice. Many large pharmaceutical companies have their own treatments for chronic diabetic foot ulcers. The space has also caused some major acquisitions. In 2011, Shire� (NASDAQ: SHPG  ) acquired�a drug called Dermagraft for the treatment of slow-healing diabetic foot ulcers, through its $750 million acquisition of�Advanced BioHealing. Dermagraft has been a rather lucrative product for Shire, with $153.8 million in sales�last year. As the market continues to grow, I would look for more partnerships with large pharmaceutical companies, and of course more research and development dollars being devoted toward the chronic diabetic foot ulcers indication.

Top Income Companies To Buy For 2015: San Miguel Brewery Hong Kong Ltd (MBR)

San Miguel Brewery Hong Kong Limited is a Hong Kong-based company engaged in the manufacture and distribution of bottled, canned and draught beers. The Company operates in two segments: The Hong Kong operation mainly represents the manufacture and distribution of own brewed beer products and distribution of imported beer products in Hong Kong and overseas, and the mainland China operation mainly represents the manufacture and distribution of own brewed beer products in the southern part of the People�� Republic of China and overseas. Its subsidiaries include Best Investments International Inc., Hongkong Brewery Limited, Ravelin Limited, San Miguel (Guangdong) Limited, Guangzhou San Miguel Brewery Company Limited, San Miguel Shunde Holdings Limited and San Miguel (Guangdong) Brewery Company Limited. Advisors' Opinion:

• [By Geoffrey Seiler]

  This was a solid quarter from Aetna, highlighted by much stronger-than-expected results from its Commercial and Medicaid segments. The rebound in the Medicaid medical benefits ratio (MBR) was particularly notable.